ProCE Banner Activity

BREEZE-AD5 Study Results: Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis

Slideset Download
Conference Coverage
Significantly improved skin inflammation, pain, itch, sleep, and quality-of-life outcomes in patients with moderate to severe AD treated with baricitinib vs placebo.

Released: August 11, 2020

Expiration: August 10, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by educational grants from

AbbVie Inc.

Pfizer, Inc.